|Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China|
|Wang, Kaidi1; Xu, Li2; Yuan, Zhilan3; Yao, Ke4; Zhao, Junmei5; Xu, Liang6; Fang, Aiwu7,9; Zhang, Mingzhi8; Wu, Lingling10; Ji, Jian11; Hou, Jiamin12,13; Liu, Qing14; Sun, Xinghuai1|
|关键词||Bimatoprost Glaucoma Ocular Hypertension Intraocular Pressure Conjunctival Hyperemia|
|WOS标题词||Science & Technology|
|关键词[WOS]||PROSTAGLANDIN ANALOGS ; TRAVOPROST 0.004-PERCENT ; CLINICAL-TRIAL ; RISK-FACTORS ; LATANOPROST ; MULTICENTER ; PROGRESSION ; TOLERABILITY ; INTERVENTION ; METAANALYSIS|
Background: To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy.
Methods: Two hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia.
Results: Among 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 +/- 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 +/- 2.8 mmHg (9.5%) to 6.4 +/- 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity.
Conclusions: Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.
|资助机构||Allergan Information Consulting (Shanghai) Co., Ltd.|
|作者单位||1.Allergan Informat Consulting Shanghai Co Ltd, Shanghai, Peoples R China|
2.Fourth Peoples Hosp Shenyang, Dept Ophthalmol, Shenyang, Peoples R China
3.Peoples Hosp Jiangsu, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China
4.Shanxi Eye Hosp, Taiyuan, Peoples R China
5.Wenzhou Med Coll, Hosp Eye, Wenzhou, Peoples R China
6.Chinese Univ Hong Kong, Shantou, Peoples R China
7.Peking Univ, Ctr Eye, Hosp 3, Beijing 100871, Peoples R China
8.Tianjin Med Univ, Ctr Eye, Tianjin, Peoples R China
9.Xiamen Univ, Eye Inst, Xiamen, Peoples R China
10.Xiamen Univ, Xiamen Eye Ctr, Xiamen, Peoples R China
11.Fudan Univ, Shanghai Med Coll, Eye ENT Hosp, Shanghai, Peoples R China
12.Zhejiang Univ, Coll Med, Affiliated Hosp 2, Eye Ctr, Hangzhou 310003, Zhejiang, Peoples R China
13.Capital Univ Med Sci, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China
14.Shantou Univ Shantou, Joint Shantou Int Eye Ctr, Shantou, Peoples R China
|Wang, Kaidi,Xu, Li,Yuan, Zhilan,et al. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China[J]. BMC OPHTHALMOLOGY,2014,14.|
|APA||Wang, Kaidi.,Xu, Li.,Yuan, Zhilan.,Yao, Ke.,Zhao, Junmei.,...&Sun, Xinghuai.(2014).Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.BMC OPHTHALMOLOGY,14.|
|MLA||Wang, Kaidi,et al."Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China".BMC OPHTHALMOLOGY 14(2014).|